Navigation Links
12-month ATLANTA trial data show sustained benefit of Catania Stent
Date:10/14/2008

WASHINGTON, Oct. 13 -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days.

The ATLANTA Trial is a first-in-man (FIM), prospective, single center, non-randomized, single-arm study involving 55 patients (76 lesions) treated with the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F surface modification for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries. The trial was sponsored by CeloNova BioSciences, Inc., maker of the CATANIA™ stent.

At 12 months, in an unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent (five of 74 lesions analyzed at twelve months). Of note, all patients stopped dual anti-platelet therapy after 30 days, but continued aspirin (100 mg/d) throughout the 12-month period.

The acute angiographic and procedural success rate in the ATLANTA Trial was 100 percent. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound (IVUS) data for all patients immediately after stent implantation and at 6-month follow-up. Further analysis of 1,904 cross sections (19,028 struts) by investigators using Optimal Coherence Tomography at baseline and again at 6-month follow-up in a subset of 15 randomly selected patients revealed complete endothel
'/>"/>

Contact: David Patti
dpatti@storchmurphy.com
908-276-0777
The Storch Murphy Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. DHS Begins Collecting 10 Fingerprints From International Visitors at Hartsfield-Jackson Atlanta International Airport
2. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
3. Vitamin E trials fatally flawed
4. Research team says extraterrestrial impact to blame for Ice Age extinctions
5. Trial seeks genetic fingerprint for predicting drug effectiveness
6. The industrial space age
7. Contrast agent trials in swine
8. Small-scale fishing in Mexico rivals industrial fisheries in accidental turtle deaths
9. Study of African traditional medicine will begin world-first clinical trial
10. New model revises estimates of terrestrial carbon dioxide uptake
11. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... , January 28, 2015 ... Analysis, Size And Segment Forecasts To 2020 has Been ... IR camera market is expected to reach USD 5.10 ... Grand View Research, Inc. IR cameras help identify the ... are expected to witness surging demand in medical imaging ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... help to raise the offspring of other group members are ... for more distant kin, a new study has found., The ... Australia, the chestnut-crowned babbler, also found that these birds work ... the young of less-related group members., The findings, published in ...
... Elser today received the G. Evelyn Hutchinson Award, the ... the July 2012 Association for the Sciences of Limnology ... Lake Biwa, Otsu, Shiga, Japan. The Hutchinson Award is ... 10 years of excellence in limnology (the study of ...
... CORVALLIS, Ore. Scientists have discovered two viruses that appear ... are important for coral growth and health, and they say ... of coral ecosystems around the world. These viruses, ... have been shown for the first time to clearly be ...
Cached Biology News:Helping family is key for social birds 2ASU ecologist receives prestigious global award for water research 2ASU ecologist receives prestigious global award for water research 3Viruses linked to algae that control coral health 2
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... for its newly developed Bruton,s tyrosine kinase (BTK) ... completed. The results of these preclinical evaluations have ... Administration. The feedback received from the Agency is ... study. Additional preclinical work is required to begin ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)... BERKELEY, Calif. , Feb. 27, 2015  Steep ... in the US and internationally, intends to open a ... Albuquerque, New Mexico , bringing advanced scientific ... of cannabis. Steep Hill is currently the ... Health to conduct potency and contaminant testing in order ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... , Overview ... basis of the separation and purification of a number of biological ... for protein A, or a protein may be purified on the ... Typically, these purifications take place in a chromatographic column with a ...
... Purpose , Increased ... LC/MS/MS System for N-in-1 experiments. Patented LINAC collision cell technology plays a ... sensitivity. , Overview , ... LC/MS/MS has made an important impact is in N-in-1 studies (also referred ...
... Abstract , ... and widely used tools in the biological sciences. In ... cytokines in the tissue culture supernatants of treated cells. ... (HTS) because they require cumbersome manipulations. Applied Biosystems has ...
Cached Biology Technology:Use of ZipTip Pipette Tips for Microscale Affinity Mass Spectrometry 2Use of ZipTip Pipette Tips for Microscale Affinity Mass Spectrometry 3Detection of N-in-1 Experiments: Extending the Range of N Using the API 3000 LC/MS/MS System 2Detection of N-in-1 Experiments: Extending the Range of N Using the API 3000 LC/MS/MS System 3Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 2Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 3Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 4Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 5
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Mouse monoclonal antibody to RNase L...
Anti (porcine) Vitronectin...
... Rabbit polyclonal to BMP2 BMP2 ... beta (TGFB) superfamily. Bone morphogenic protein ... candidate gene for the autosomal dominant ... Immunogen: Synthetic peptide: ...
Biology Products: